On 2 May 2018, Abcam plc announced that it had made a proposal in relation to a possible offer for Horizon Discovery at 181 pence per share. This reflected Abcam’s strong interest in pursuing strategic expansion in the gene editing market, which the Directors of Abcam believe to be a highly complementary adjacency to Abcam’s existing business. The Proposal was rejected by the Board of Horizon Discovery.
Abcam continues to execute on its vision to be the most influential life science company for researchers worldwide, and remains committed to expanding its reach and influence globally. However, it has always been Abcam’s intention to remain disciplined about value whilst working towards a transaction with the recommendation of the Board of Horizon Discovery.
On 8 May 2018, Horizon Discovery published its preliminary results for the year ended 31 December 2017. Having considered those results and Horizon Discovery’s statement on 2 May 2018 regarding the Board of Horizon Discovery’s view that there is little strategic rationale to combining the two companies, Abcam confirms that it does not intend to make an offer for Horizon Discovery.
Read the full story here
Abcam confirms it does not intend to make an offer for Horizon Discovery
9 May 2018
Abcam plc has made a statement today regarding Horizon Discovery Group plc.